Teva Pharmaceutical Industries Limited (NYSE:TEVA) is one of the best growth stocks under $50 to buy now. On September 5, J.P. Morgan analyst Chris Schott maintained a Buy rating on Teva Pharmaceutical Industries Limited (NYSE:TEVA) and set a price target of $23.00. Teva Pharmaceutical Industries Limited (TEVA): Among Small-Cap Healthcare Stocks Hedge Funds is Buying On August 28, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced the FDA approval and U.S. launch of Generic Saxenda, the first-e ...